Bristol-Myers Squibb says Iza-Bren doubles median PFS versus chemotherapy in Phase 3 Panku-Lung01
BMY•Bristol-Myers Squibb said Iza-Bren doubled median progression-free survival to 11.1 months versus 5.7 months with chemotherapy in the Phase 3 Panku-Lung01 study. The company also reported a 60.2% CORR and 10.4-month MDOR with Iza-Bren, and said 1.9% discontinued treatment due to TRAEs.
1. Trial results
Bristol-Myers Squibb said Iza-Bren produced median progression-free survival of 11.1 months, compared with 5.7 months for chemotherapy, in previously treated patients with EGFR-mutated non-small cell lung cancer. CORR by BICR was 60.2% versus 34.5%, and MDOR was 10.4 versus 5.7 months; the company described the safety profile as manageable and said 1.9% discontinued due to TRAEs.
